• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英格兰东南部的肌萎缩侧索硬化症:一项基于人群的研究。英格兰东南部肌萎缩侧索硬化症登记处(SEALS登记处)。

Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry).

作者信息

Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell R W, Howard R, Clarke J, Sakel M, Ampong M-A, Shaw C E, Leigh P N, Al-Chalabi A

机构信息

MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, London, UK.

出版信息

Neuroepidemiology. 2007;29(1-2):44-8. doi: 10.1159/000108917. Epub 2007 Sep 24.

DOI:10.1159/000108917
PMID:17898523
Abstract

BACKGROUND/AIMS: We aimed to estimate the incidence and prevalence of amyotrophic lateral sclerosis (ALS) in the South East of England. The reported incidence of ALS varies between 0.44 and 3.2 per 100,000 person years. This can partly be explained by differences in design and diagnostic criteria used. There is little population data concerning England, particularly the South East.

METHODS

A population study of South-East England (total population: 2,890,482) was carried out and multiple sources including our tertiary centre and district general hospitals were used for complete case ascertainment.

RESULTS

Between 1 January 2002 and 30 June 2006 we identified 138 people (76 males; 62 females) with a new diagnosis of ALS, giving a crude incidence of 1.06 per 100,000 person years. The projected age- and gender-adjusted annual incidence rate for England and Wales was 1.10 (95% CI 0.80-1.40). 142 people were alive on 30 June 2006, giving a point prevalence of 4.91 per 100,000 population.

CONCLUSION

Our incidence and prevalence rates are similar to those reported in comparable studies from other countries. This argues against the role of a specific exogenous factor in the aetiology of ALS in South-East England.

摘要

背景/目的:我们旨在估算英格兰东南部肌萎缩侧索硬化症(ALS)的发病率和患病率。报道的ALS发病率为每10万人年0.44至3.2例。这部分可以通过所采用的研究设计和诊断标准的差异来解释。关于英格兰,尤其是东南部,几乎没有人口数据。

方法

对英格兰东南部(总人口:2,890,482)进行了一项人口研究,并利用包括我们的三级中心和地区综合医院在内的多个来源来确定全部病例。

结果

在2002年1月1日至2006年6月30日期间,我们确定了138例新诊断为ALS的患者(76例男性;62例女性),粗发病率为每10万人年1.06例。英格兰和威尔士经年龄和性别调整后的预计年发病率为1.10(95%可信区间0.80 - 1.40)。在2006年6月30日有142人存活,点患病率为每10万人口4.91例。

结论

我们的发病率和患病率与其他国家类似研究报道的结果相似。这表明在英格兰东南部ALS的病因中不存在特定外源性因素的作用。

相似文献

1
Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry).英格兰东南部的肌萎缩侧索硬化症:一项基于人群的研究。英格兰东南部肌萎缩侧索硬化症登记处(SEALS登记处)。
Neuroepidemiology. 2007;29(1-2):44-8. doi: 10.1159/000108917. Epub 2007 Sep 24.
2
The association between ALS and population density: A population based study.肌萎缩侧索硬化症与人口密度之间的关联:一项基于人群的研究。
Amyotroph Lateral Scler. 2010 Oct;11(5):435-8. doi: 10.3109/17482961003754552.
3
Geographical clustering of amyotrophic lateral sclerosis in South-East England: a population study.英格兰东南部肌萎缩侧索硬化症的地理聚集性:一项人群研究。
Neuroepidemiology. 2009;32(2):81-8. doi: 10.1159/000177032. Epub 2008 Nov 27.
4
Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015.亚特兰大都会区肌萎缩侧索硬化症(ALS)监测:2009-2011 年的发病率和患病率,以及到 2015 年的生存特征。
Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):123-130. doi: 10.1080/21678421.2019.1682614. Epub 2019 Dec 4.
5
Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011.2010 - 2011年美国肌萎缩侧索硬化症的患病率
MMWR Suppl. 2014 Jul 25;63(7):1-14.
6
Secular Trends of Amyotrophic Lateral Sclerosis: The Piemonte and Valle d'Aosta Register.肌萎缩侧索硬化症的长期趋势:皮埃蒙特和瓦莱达奥斯塔登记处
JAMA Neurol. 2017 Sep 1;74(9):1097-1104. doi: 10.1001/jamaneurol.2017.1387.
7
Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany.德国莱茵兰-普法尔茨州肌萎缩侧索硬化症的发病率。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):269-74. doi: 10.3109/21678421.2014.887733. Epub 2014 Feb 26.
8
Motor Neuron Disease Register for England, Wales and Northern Ireland-an analysis of incidence in England.英格兰、威尔士和北爱尔兰运动神经元病登记处-对英格兰发病率的分析。
Amyotroph Lateral Scler Frontotemporal Degener. 2021 Feb;22(1-2):86-93. doi: 10.1080/21678421.2020.1812661. Epub 2020 Sep 17.
9
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.肌萎缩侧索硬化症的患病率 - 美国,2012-2013 年。
MMWR Surveill Summ. 2016 Aug 5;65(8):1-12. doi: 10.15585/mmwr.ss6508a1.
10
Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.肌萎缩侧索硬化症作为一个多步骤过程的分析:基于人群的建模研究。
Lancet Neurol. 2014 Nov;13(11):1108-1113. doi: 10.1016/S1474-4422(14)70219-4. Epub 2014 Oct 7.

引用本文的文献

1
Brain-body mechanisms contribute to sexual dimorphism in amyotrophic lateral sclerosis.大脑-身体机制导致肌萎缩侧索硬化症的性别二态性。
Nat Rev Neurol. 2024 Aug;20(8):475-494. doi: 10.1038/s41582-024-00991-7. Epub 2024 Jul 4.
2
Target Identification of a Class of Pyrazolone Protein Aggregation Inhibitor Therapeutics for Amyotrophic Lateral Sclerosis.一类用于肌萎缩侧索硬化症的吡唑啉酮蛋白聚集抑制剂疗法的靶点鉴定
ACS Cent Sci. 2023 Dec 20;10(1):87-103. doi: 10.1021/acscentsci.3c00213. eCollection 2024 Jan 24.
3
Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: Prospective cohort study.
系统性炎症与随后发生的肌萎缩侧索硬化症风险:前瞻性队列研究。
Brain Behav Immun. 2023 Nov;114:46-51. doi: 10.1016/j.bbi.2023.07.026. Epub 2023 Aug 4.
4
Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: prospective cohort study.全身炎症与肌萎缩侧索硬化症的后续风险:前瞻性队列研究
medRxiv. 2023 Mar 10:2023.03.06.23286852. doi: 10.1101/2023.03.06.23286852.
5
Phenome-wide genetic-correlation analysis and genetically informed causal inference of amyotrophic lateral sclerosis.肌萎缩侧索硬化症的表型全基因组遗传关联分析和基于遗传的因果推断。
Hum Genet. 2023 Aug;142(8):1173-1183. doi: 10.1007/s00439-023-02525-5. Epub 2023 Feb 11.
6
Age of Onset and Length of Survival of Queensland Patients with Amyotrophic Lateral Sclerosis: Details of Subjects with Early Onset and Subjects with Long Survival.昆士兰肌萎缩侧索硬化症患者的发病年龄和存活时间:早发型患者和长期存活患者的详细情况。
Neurodegener Dis. 2022;22(3-4):104-121. doi: 10.1159/000528875. Epub 2022 Dec 30.
7
Amyotrophic lateral sclerosis in seven provinces of Chinese mainland: A cross-sectional survey from 2015 to 2016.中国大陆七个省份的肌萎缩侧索硬化症:2015年至2016年的横断面调查
Front Aging Neurosci. 2022 Sep 15;14:946353. doi: 10.3389/fnagi.2022.946353. eCollection 2022.
8
Effect of alpha-mangostin in the prevention of behavioural and neurochemical defects in methylmercury-induced neurotoxicity in experimental rats.α-山竹黄酮对预防实验大鼠甲基汞诱导神经毒性所致行为和神经化学缺陷的作用。
Toxicol Rep. 2022 Apr 22;9:977-998. doi: 10.1016/j.toxrep.2022.04.023. eCollection 2022.
9
Modeling Amyotrophic Lateral Sclerosis Progression: Logic in the Logit.肌萎缩侧索硬化症进展建模:对数几率中的逻辑
Cureus. 2022 May 10;14(5):e24887. doi: 10.7759/cureus.24887. eCollection 2022 May.
10
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.运动神经元病/肌萎缩侧索硬化症患者流涎(唾液过多)的治疗。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3.